NCT02916901已完成1 期
A Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Cross-over Phase I Clinical Trial to Investigate the Effect of CKD-519 on 24-h Ambulatory Blood Pressure After Oral Administration in Healthy Adult Volunteers
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Change in 24h average SBP and DBP from baseline to Day 14 Each time point is as following: Daytime: 06:00~21:59 Nighttime: 22:00~05:59
研究概览
简要总结
The purpose of this study is to determine influence of CKD-519 on 24-h ambulatory blood pressure after oral administration in healthy adult volunteers.
详细描述
A randomized, double-blind, placebo-controlled, multiple dosing, cross-over phase I clinical trial to investigate the effect of CKD-519 on 24-h ambulatory blood pressure after oral administration in healthy adult volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Between 19 aged and 55 aged in healthy adult
- •Body weight more than 55kg in male, 50kg in female
- •Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)
- •If female, must include more than one among the items
- •The menopause(there is no natural menses for at least 2 years)
- •Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition
- •If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms and do not sperm donation until two months during clinical trials and after the final dosage of investigational products
- •Those who fully understand about this clinical trials after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent.
排除标准
- •Have clinically significant disease that hepatobiliary system(severe hepatic impairment, etc), kidney(severe renal impairment, etc), nervous system, immune system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular system(heart failure, etc) or mental illness, or a history of mental disease.
- •Have a gastrointestinal disease history that can effect drug absorption(Crohn's disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)
- •Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of drugs or additives.
- •An impossible one who participates in clinical trial including screening tests(medical history taking, BP, 12-lead ECG, physical examination, blood&urine laboratory test result) before 28 days the taking investigational Products.
- •Defined by the following laboratory parameters
- •AST, ALT>1.25 upper limit of normal range
- •Total bilirubin>1.5 upper limit of normal range
- •CPK>1.5 upper limit of normal range
- •eGFR(using by MDRD method)<60mL/min/1.73m2
- •Sitting SBP > 140mmHg or < 90mmHg, sitting DBP > 90mmHg or < 60mmHg, after 5 minutes break.
- •The difference in DBP>10mmHg or SBP >20mmHg at the screening period
- •Drug abuse or have a history of drug abuse shows a positive for urine drug test.
- •Pregnant or lactating women.
- •A heavy caffeine consumer(caffeine>5 cups/day), alcohol consumer(alcohol>210g/week),
- •smoker(except the one who have stopped smoking more than 90days before beginning of study treatment)
- •Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of subjects.
- •Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates etc.) within 30 days.
- •Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days before the beginning of study treatment)
- •Subject who treated with any investigational drugs within 90 days before the beginning of study treatment
- •Previously donate whole blood within 60 days or component blood within 30 days.
- •Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
- •An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason
研究组 & 干预措施
CKD-519 200mg
Experimental
CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
干预措施: CKD-519 200mg (Drug)
Placebo
Placebo Comparator
placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change in 24h average SBP and DBP from baseline to Day 14 Each time point is as following: Daytime: 06:00~21:59 Nighttime: 22:00~05:59
时间窗: 14days
次要结局
- Cmax,ss of CKD-519(0(predose)~24 at day15)
- AUCτ,ss of CKD-519(0(predose)~24 at day15)
- Tmax,ss of CKD-519(0(predose)~24 at day15)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)Ambulatory Blood PressureNCT00565006Merck Sharp & Dohme LLC22
已完成
4 期
Caduet in an Untreated Subject PopulationHypertensionDyslipidemiaNCT00332761Pfizer's Upjohn has merged with Mylan to form Viatris Inc.220
已完成
3 期
A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure MonitoringFibromyalgiaNCT00618956Forest Laboratories321
Unknown
不适用
Central and Peripheral Blood Pressure in Treatment of Obstructive Sleep Apnea.Obstructive Sleep ApneaHypertensionNCT02078778Erling Bjerregaard Pedersen20
已完成
3 期
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.Essential HypertensionNCT00343551Novartis654